Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes

Diabetes Care

Volumn 32, Issue 6, 2009, Pages 1037-1042

  Morrato, Elaine H ^a   Newcomer, John W ^b   Kamat, Siddhesh ^c   Baser, Onur ^d   Harnett, James ^e   Cuffel, Brian ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HEALTHCORE INC   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONSENSUS; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICAL SOCIETY; MENTAL HEALTH; METABOLISM; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DIABETES COMPLICATIONS; FEMALE; HUMANS; LIPIDS; MALE; MENTAL DISORDERS; MENTAL HEALTH; MIDDLE AGED; RISK FACTORS; SOCIETIES, MEDICAL; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 66549117611     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1720     Document Type: Article

References (23)

1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1-93
2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schiz Res 2005;80:19-32 (Pubitemid 41587460)
3. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Res 2005;80:45-53 (Pubitemid 41587462)
4. Colton C, Manderscheid R. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. In Prev Chronic Dis 2006 [serial online]. Available from http://www.cdc.gov/pcd/issues/2006/apr/05-0180.htm. Accessed 25 June 2008
5. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007;298:1794-1796 (Pubitemid 47598448)
6. Druss BG, Bradford WD, Rosenheck R, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001;58:565-572 (Pubitemid 32523736)
7. Goff DC CC, Evins AE, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sacks FM. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66:183-194 (Pubitemid 40314324)
8. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220 (Pubitemid 29193917)
9. Frayne SM, Halanych JH, Miller DR, Wang F, Lin H, Pogach L, Sharkansky EJ, Keane TM, Skinner KM, Rosen CS, Berlowitz DR. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005;165:2631-2638 (Pubitemid 41785061)
10. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62:15-26
11. Lean M, Pajonk F. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003;26:1597-1605 (Pubitemid 36929197)
12. U.S. Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News, 2004 [article online]. Available from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show= 28#4. Accessed 14 April 2008
13. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity anddiabetes.Diabetes Care2004;27:596-601
14. Morrato E, Newcomer J, Allen R, Valuck R. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008;69:316-322
15. Agency for Healthcare Research and Quality. HCUP clinical classifications software (CCS) for ICD-9-CM fact sheet [article online], 2007. Available from http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccsfactsheet.jsp
16. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27:299-309 (Pubitemid 34989269)
17. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health 2006;9:377-385 (Pubitemid 44511151)
18. Sikka R, Zia F, Aubert R. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457 (Pubitemid 41022729)
19. Timmermans S, Mauck A. The promises and pitfalls of evidence-based medicine. Health Aff (Millwood) 2005;24:18-28 (Pubitemid 40169771)
20. Morrato EH, Libby AM, Orton HD, de- Gruy FV, Brent DA, Allen RR, Valuck RJ. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008;165:42-50
21. Cabana MD, Rand CS, Powe NR,WuAW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999;282:1458-1465
22. Ketter TA, Haupt DW. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr Med Res Opin 2006;22:2345-2353
23. Suppes T, McElvoy S, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 U.S. psychiatrists. Psychopharmacol Bull 2007;40:22-37